Avectas is accelerating the future of cell therapy with a flexible manufacturing platform that engineers healthier and more functional cells for patients. Avectas has developed Solupore, an optimized non-viral transfection process aligned with GMP manufacturing to advance ex vivo cell therapy workflows.
Our vision is to develop integrated processes incorporating scale up and scale out systems to address the manufacturing challenges of time and cost, whilst maintaining superior cell health and function.
Solupore®
non-viral delivery platform for cell engineering
The Solupore, non-viral delivery platform, engineered by Avectas, enables the next generation of cell therapies, expanding the possibilities for complex editing workflows in cell therapy manufacturing. Solupore can facilitate sequential delivery and multiplex editing enabling applications in autologous CAR-T cell therapies and in the reprogramming of blood cells to iPS cells.
Upcoming Events
Our Partners
Partnerships are essential to ensure better patient outcomes, and we are actively seeking to engage with companies and researchers who are developing these lifesaving gene-modified cell therapy products. Find our current list on our partner page.
Avectas' Solupore® platform offers a cell engineering solution for next-generation cell therapies. Partnerships are essential to ensure better patient outcomes, and we are actively seeking to engage with companies and researchers who are developing these life-saving gene-modified cell therapy products. If you would like to learn more about working with Avectas, please get in touch with us.